Reassignment of the human aldehyde dehydrogenase ALDH8A1 (ALDH12) to the kynurenine pathway in tryptophan catabolism

Ian Davis†, Yu Yang†, Daniel Wherritt†, and Aimin Liu†,*

From the †Department of Chemistry, University of Texas at San Antonio, San Antonio, Texas 78249

Running title: Extension of the mammalian kynurenine pathway

*To whom correspondence should be addressed: Aimin Liu: Department of Chemistry, University of Texas at San Antonio, San Antonio TX 78249; Feradical@utsa.edu; Tel. (210) 458-7062; Fax. (210) 458-7428.

Keywords: aldehyde dehydrogenase, 2-aminomuconate semialdehyde dehydrogenase, tryptophan catabolism, NAD biosynthesis, retinal metabolism, biodegradation, serotonin, neurological disease, kynurenine pathway, retinal dehydrogenase

ABSTRACT

The kynurenine pathway is the primary route for L-tryptophan degradation in mammals. Intermediates and side products of this pathway are involved in immune response and neurodegenerative diseases. This makes the study of enzymes, especially those from mammalian sources, of the kynurenine pathway worthwhile. Recent studies on a bacterial version of an enzyme of this pathway, 2-aminomuconate semialdehyde (2-AMS) dehydrogenase (AMSDH), have provided a detailed understanding of the catalytic mechanism and identified residues conserved for muconate semialdehyde recognition and activation. Findings from the bacterial enzyme have prompted the reconsideration of the function of a previously identified human aldehyde dehydrogenase, ALDH8A1 (or ALDH12), which was annotated as a retinal dehydrogenase based on its ability to preferentially oxidize 9-cis-retinal over trans-retinal. Here, we provide compelling bioinformatics and experimental evidence that human ALDH8A1 should be reassigned to the missing 2-AMS dehydrogenase of the kynurenine metabolic pathway. For the first time, the product of the semialdehyde oxidation by AMSDH is also revealed by NMR and high-resolution MS. We found that ALDH8A1 catalyzes the NAD⁺-dependent oxidation of 2-AMS with a catalytic efficiency equivalent to that of AMSDH from the bacterium Pseudomonas fluorescens. Substitution of active-site residues required for substrate recognition, binding, and isomerization in the bacterial enzyme resulted in human ALDH8A1 variants with 100-fold increased \( K_m \) or no detectable activity. In conclusion, this molecular study establishes an additional enzymatic step in an important human pathway for tryptophan catabolism.

L-Tryptophan, an essential amino acid, has several metabolic fates in mammals: a building block for proteins, the precursor for serotonin and melatonin, and its complete catabolism through the kynurenine pathway (KP) to pyruvate via alanine, acetoacetate via glutaryl-CoA (1), NAD/NADH via quinolinic acid (QA) (2), and several neurologically active compounds. Various kynurenine pathway metabolites are linked to innate immune response and both neuro-excitatory and neuro-depressive effects (3-6). Due to its potential medical significance, the KP has received increasing attention. The first and committing enzymes, tryptophan or indolamine dioxygenase are active drug targets with inhibitors in clinical trials (5,7,8). Recently, a downstream enzyme of the KP (Scheme 1), 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) has received attention as a potential drug target (6). Inhibition of ACMSD has been shown to slow down the reaction competing with QA formation and boost cellular NAD(H) levels (9).

To date, the KP pathway genes and their corresponding enzymes have not been identified beyond ACMSD (10,11), even though the metabolic pathway was published 53 years ago and has made its way into numerous biochemistry textbooks. One limiting factor for studying KP enzymes is that the identification of...
Extension of the mammalian kynurenine pathway

their mammalian genes has proved difficult. Initial characterization of the KP enzymes was performed from animal liver extracts (1). While these studies verified the activities and transformations of the KP, they were unable to provide much insight into the individual enzyme structures and mechanisms. Study of the KP enzymes stagnated until the discovery of an analogous KP in some bacteria (12-17) and that 2-nitrobenzoate biodegradation shares many of the downstream proteins with the eukaryotic kynurenine pathway (18-20). An additional difficulty for studying the KP enzymes, especially downstream proteins, is that several of the metabolic intermediates of the pathway are unstable and commercially unavailable. As shown in Scheme 1, the substrates for ACMSD and its downstream neighbor, 2-aminomuconate semialdehyde dehydrogenase (AMSDH), are both unstable and spontaneously cyclize via a pericyclic reaction to their respective pyridine products, QA and picolinic acid (PA) (2).

Despite the difficulties mentioned above, much progress has been made in understanding the mechanisms of KP enzymes. Recently, AMSDH from *Pseudomonas fluorescens* (pfAMSDH) identified from 2-nitrobenzoate biodegradation pathway has been studied at the molecular level. Crystal structures of the resting enzyme, NAD⁺-bound complex, ternary complex, catalytic thioacyl and thiohemiacetal intermediates, and several mutants have been reported (21). A hidden isomerase activity of AMSDH has also been uncovered (22). Additionally, the study of pfAMSDH revealed that in addition to active-site residues that are broadly conserved across all aldehyde dehydrogenases, the hydroxymuconate semialdehyde dehydrogenase (HMSDH) family possesses two conserved arginine residues that are involved in substrate recognition and an isomerization activity (22).

In this work, we have identified a human enzyme annotated as a retinal dehydrogenase (ALDH8A1) that carries the hallmarks of an aminomuconate semialdehyde dehydrogenase. An overexpression system was constructed, and recombinant ALDH8A1 was tested for activity with two muconic semialdehyde substrates. The activity of selected active site variants was also investigated, and the reaction products were verified with NMR and high-resolution MS. All evidence suggests that ALDH8A1 should be reconsidered as the aldehyde dehydrogenase of the kynurenine pathway of tryptophan catabolism.

Results and Discussion

Identification of ALDH8A1 as a potential member of the kynurenine pathway

To continue studying the KP pathway at the molecular level, the next pressing step is to identify a mammalian AMSDH, especially the human version. We performed a BLAST search with pfAMSDH as the search sequence. The results revealed a human protein, ALDH8A1 (initially designated ALDH12), with 44% amino acid sequence identity to pfAMSDH. However, ALDH8A1 is currently annotated in the NCBI gene database as a retinal dehydrogenase. It was assigned as cis-retinal dehydrogenase based on its ability to oxidize 9-cis retinal faster than all-trans retinal, even though it was most active with benzaldehyde rather than the retinal substrates (23). It was also noted in the original characterization that ALDH8A1 shares the closest nucleotide and protein sequence similarity with AMSDH, but it was not tested for such activity, presumably due to difficulty obtaining 2-aminomuconate semialdehyde (2-AMS). Here, we present evidence that ALDH8A1 may be more appropriately considered human AMSDH of the KP. AMSDH belongs to the hydroxymuconate semialdehyde dehydrogenase (HMSDH) family. Our alignment of ALDH8A1 against AMSDH and several members of the HMSDH family showed not only high overall conservation, but also that in addition to residues required for aldehyde dehydrogenase activity (Asn155, Glu253, and Cys287), residues responsible for substrate recognition only in HMSDH enzymes are conserved in ALDH8A1, namely Arg109 and Arg451 (Figure 1).

A homology structure model of ALDH8A1 was built using the iTASSER server (24). An
overlay of the homology model and pfAMSDH is shown in Figure 2A. The model shows full coverage of the human enzyme sequence which overlays well with the bacterial enzyme with an RMSD of 1.15 Å for 472 C-alpha carbons. In addition, all of the catalytically essential active-site residues from pfAMSDH (Arg109, Asn155, Glu253, Cys287, Arg451 by ALDH8A1 numbering) are in the same location in the homology model as in the pfAMSDH structure (Figure 2B).

**ALDH8A1 can perform the NAD⁺-dependent oxidation of 2-aminomuconic semialdehyde**

The next question to arise is whether or not ALDH8A1 is able to catalyze the NAD⁺-dependent oxidation of 2-AMS to 2-aminomuconate (2-AM). Pursuant to this end, an overexpression system was generated. The synthesized gene for human ALDH8A1 was ligated into pET-28a(+) vector with a cleavable N-terminal His6-tag and transformed into *E. coli* BL21(DE3) competent cells. The expressed protein was purified by Ni-affinity chromatography (Figure 3A) and its ability to oxidize 2-AMS in a coupled enzyme assay with ACMSD was tested. As shown in Figure 3B, ACMS has a broad absorbance band at 360 nm. Upon ACMSD-catalyzed decarboxylation to 2-AMS, the absorbance maximum red-shifted to 380 nm and then decayed as 2-AMS non-enzymatically converted to PA. The inclusion of purified ALDH8A1 and 1 mM NAD⁺ in an otherwise identical assay prevented the redshift, and instead, a broad absorbance band around 360 nm was observed which has been previously assigned as the oxidized product, 2-AM, and NADH (Figure 3C) as per the reaction scheme shown in Figure 3D. These results resemble what were observed from pfAMSDH and show that ALDH8A1 is able to rapidly oxidize 2-AMS in solution. The presence of the expected product in the coupled enzyme assay was also verified by NMR spectroscopy. As shown in Figure 4, the reaction mixture contained resonances consistent with 2-AM and expected cross peaks in the ¹H-¹H COSY spectrum to show connectivity. Proton resonances were assigned based on similarity with 2-hydroxymuconic acid, which was rigorously characterized (25).

**Characterization of the reaction product of the ALDH8A1-catalyzed reaction**

In initial studies of AMSDH, the identity of the product was inferred based on knowledge of the substrate structure and the catalytic cycle of the dehydrogenation reaction. The in crystallo characterization of the AMSDH reaction revealed that in addition to oxidation of the aldehyde to its corresponding carboxylic acid, pfAMSDH also isomerizes the 2,3-double bond inside the active site prior to substrate oxidation. In the process of trying to determine the conformation of the product of the reaction catalyzed by ALDH8A1, we noticed that the product, 2-AM (λmax 330 nm), is unstable and non-enzymatically bleaches in a single kinetic phase with a half-life of 67 min, Figure 5A. High-resolution mass spectra were acquired of the 2-AM decay product after purification by HPLC. Mass spectra were collected in negative mode, and as shown in Figure 5B, the parent ion matches tautomerized hydroxymuconate, 2-oxo-3-hexenedioate, with 2.55 ppm mass accuracy. Furthermore, fragment ions from cleaving at either side of the keto group can be observed with nominal masses of 113 and 85 Da.

The downstream enzyme of AMSDH performs deamination on 2-AM to produce 2-hydroxymuconate which is expected to tautomerize to its α,β-unsaturated ketone form, 2-oxo-3-hexenedioate, as shown in Scheme 2. The deamination reaction is not known to be coupled to any other reaction, so it is expected to be thermodynamically preferred. As such, it may proceed non-enzymatically at a slower rate. To lend credence to the proposed non-enzymatic deamination followed by tautomerization, ACMSD-AMSDH coupled enzyme assays were performed in H₂O and D₂O, and the reaction products were monitored by NMR spectroscopy, Figure 6. When performing the reaction in H₂O (Figure 6A), two doubles around 5.8 ppm and a doublet of doublets at 7.15 ppm can be observed to decay while a new doublet at 6.17 ppm and a doublet of triplets at 6.9 ppm arise. These new resonances are consistent with 2-oxo-
hexenedioate observed in the study of 2-hydroxymuconate tautomerization (25). Alternatively, upon enzymatic decarboxylation and oxidation performed in D2O by ACMSD and AMSDH, respectively, the 1H NMR spectrum shows two doublets at 7.1 and 5.8 ppm, corresponding to the protons on carbons 4 and 5 (Hb and Hc) of 2-AM, respectively (Figure 6B). The proton at the 3-position (Ha) is replaced with deuterium by running the ACMSD reaction in D2O (Scheme 3). The two doublets coalesce into a single resonance at 6.9 ppm over time. The decay of the resonance at 5.8 ppm indicates that the proton at the 5-position can eventually exchange with solvent, and the shift of the doublet at 7.1 to a singlet at 6.9 ppm implies that a chemical change takes place in addition to simple exchanging of protons for deuterons. The most likely candidate for such a chemical change is the replacement of the nitrogen at the 2-position with oxygen derived from water, i.e., deamination of 2-AM. Thus, the NMR spectra of the initial and final products of the ALDH8A1 reaction are consistent with 2-AM being the initially formed product which then spontaneously deaminates and tautomerizes.

**Determination of the kinetic parameters of ALDH8A1 and selected site-directed mutants**

Though the coupled enzyme assays presented above show that 2-AMS can serve as a substrate for ALDH8A1, such experiments are not amenable to extraction of enzymatic kinetic parameters. Instead, a substrate analogue, 2-hydroxymuconate semialdehyde (2-HMS), in which the amino group of 2-AMS has been replaced with a hydroxyl group to prevent the non-enzymatic cyclization reaction, is used to determine kinetic parameters. The 1H NMR spectrum of 2-HMS can be found in Figure 6 along with corresponding 1D-NOESY spectra which show not only through-space interactions between protons but also in-phase resonances for the enol tautomer which was previously implicated as an intermediate in the 2-3 bond isomerization reaction. The observation of resonances consistent with the enol form of 2-HMS in solution lend credence to the previously proposed tautomeration mechanism in pfAMSDH by showing that the enol form is energetically accessible. ALDH8A1 exhibits typical steady-state kinetics when acting on 2-HMS (Figure 8A). The data were fitted with the Michaelis-Menten equation to provide a \( k_{\text{cat}} \), \( K_m \), and \( k_{\text{cat}}/K_m \) of 0.42 s\(^{-1}\), 590 nM, and 7.1 \times 10^5 \text{ M}^{-1}\text{s}^{-1}, respectively. A sub-micromolar \( K_m \) is at the lower end for the KP enzymes, however such high commitment may be necessary to efficiently compete with the rapid decay of its substrate to PA.

To further investigate the specificity of ALDH8A1 for \( \alpha \)-substituted muconate semialdehydes, several active site mutants were constructed. The two strictly conserved residues among the HMSDH family previously shown to be responsible for substrate recognition and binding, Arg109, and Arg451, were mutated to alanine and their kinetic parameters for 2-HMS were determined. As summarized in Table 1, deletion of Arg109 by mutation to alanine generated a variant with a similar turnover number, but ca. 160-fold increased \( K_m \) as compared to wild-type (Figure 8B). No detectable activity could be measured for the R451A variant. Additionally, the active site asparagine (Asn155) responsible for stabilizing tetrahedral, oxyanion intermediates in general and involved in substrate isomerization in AMSDH was mutated to alanine, aspartic acid, and glutamine. The activity of the mutants was too low to determine kinetic parameters, however specific activities for N155A, N155D, and N155Q were 7.4 ± 0.1, 20 ± 1, and 0.31 ± 0.03 nmol/mg/min, respectively. Of the same mutants in pfAMSDH, N169D also showed the highest activity (22). In other aldehyde dehydrogenases, mutation of the corresponding asparagine to alanine or aspartic acid reduced the activity by ca. 1,000-fold or below detectable limits (26,27).

**Conclusion**

The human enzyme ALDH8A1 (ALDH12) was shown to catalyze the NAD\(^+\)-dependent oxidation of 2-AMS with catalytic efficiency comparable to pfAMSDH. Mutation of the active-site residues which were shown to be heavily involved with substrate recognition,
binding, and isomerization in the bacterial enzyme resulted in variants with 100-fold increased $K_m$ or no detectable activity. As such, the ALDH8A1 enzyme which was previously assigned as a *cis*-retinal dehydrogenase should be reassigned as human AMSDH. It was also shown that the reaction product, 2-AM, can spontaneously deaminate in solution, ultimately forming 2-oxo-3-hexenedioate. This work thus establishes that the aldehyde dehydrogenase of the kynurenine pathway, first discovered 53 years ago from liver extracts (1), is ALDH8A1 (ALDH12). The kynurenine pathway of tryptophan catabolic pathway in humans is therefore extended to AMSDH.

**Experimental procedures**

**Cloning and Site-directed Mutagenesis**—A DNA sequence which codes for human ALDH8A1 (accession number AF303134) was purchased from DNASU (Arizona State University) and ligated into pET28a(+) vector with NheI and HindIII restriction sites, creating a N-terminal His$_6$-tagged construct. The resultant plasmid was transformed into *Escherichia coli* cell line BL21 (DE3) which was stored at -80 °C as a 20% (v/v) glycerol stock. Overexpression systems for R109A, R451A, N155A, N155Q, and N155D were constructed by PCR overlap extension using the wild-type as the starting template. The forward primers were 5'-CCATGGACATTTCCGCGTCTGTGCAGAA and 5'-CTGCTGGCTCATCGCGGAGCTGAACCTT for R109A and R451A, respectively, and 5'-GCTGGTCTGATCAGCCCCTGGGCTTTGCACTCTACTTGCTG for N155A, N155Q, and N155D, respectively.

**Protein Preparation**—For all cultures, antibiotic selection under kanamycin was used. Cultures were started by streaking the appropriate glycerol stock onto an LB-AGAR plate which was incubated overnight at 37 °C. A single colony was selected for further incubation in 15 mL of LB-Miller broth at 37 °C with 220 rpm shaking until an OD$_{600}$ of ca. 0.6 was achieved. Then, 50 mL of LB-Miller broth was inoculated to an OD$_{600}$ of 0.0002 and allowed to incubate at 37 °C with 220 rpm shaking. Finally, once the 50 mL flask reached OD$_{600}$ of ca. 0.6, it was used to inoculate 6 L of LB-Miller broth in twelve 2 L baffled flasks to an OD$_{600}$ of 0.0002. The flasks were allowed to incubate at 37 °C with 220 rpm shaking. Upon reaching OD$_{600}$ of 0.5, isopropyl β-D-1-thiogalactopyranoside was added to a final concentration of 800 µM to induce protein expression, the temperature was lowered to 16 °C, and the culture was allowed to incubate for an additional 12 h. Cells were harvested by centrifugation at 8,000 x g and resuspended in 50 mM KPi, 150 mM NaCl buffered to pH 8.0 with 0.1% (v/v) β-mercaptoethanol. Protein was released by cell disruption (LS-20, Microfluidics), and the cell debris was removed by centrifugation at 27,000 x g.

The protein of interest was purified by nickel affinity chromatography. Clarified, cell-free extract was applied to a Ni-NTA column and eluted with an imidazole gradient. The running and elution buffers were 50 mM KPi, 150 mM NaCl buffered to pH 8.0 with 5 mM 1,4-dithiothreitol, with the elution buffer also containing 500 mM imidazole. The purified protein was then desalted to 25 mM HEPES buffer pH 7.5, 5 mM 1,4-dithiothreitol, 1 mM NAD$^+$, 5% glycerol (w/v), concentrated to ca. 1 mM by 30 kDa centrifugal filters, flash-frozen in liquid nitrogen and stored at -80 °C until use. ACMSD used for coupled-enzyme assays was prepared as previously reported (11,28,29).

**Kinetic Assays**—The substrate analog 2-hydroxymuconic semialdehyde was prepared as previously reported (21). Briefly, 3-hydroxyanthalnic acid is converted to 2-amino-3-carboxymuconic semialdehyde by purified 3-hydroxyanthranilic acid dioxygenase. 2-amino-3-carboxymuconic semialdehyde can then be non-enzymatically converted to 2-hydroxymuconic semialdehyde by lowering the pH below 2. After conversion, the solution is neutralized, and excess enzyme is removed by filtration.
The coupled enzyme assays were initiated by addition of excess ACMSD (1 µM) to rapidly convert all ACMS to 2-AMS which is in turn converted to 2-amino-3-muconic acid by ALDH8A1. In the absence ALDH8A1 and 1 mM NAD^+, the 2-AMS non-enzymatically decays to picolinic acid. Catalytic parameters were obtained using 2-HMS as the substrate. The decrease in absorbance as 2-HMS (λmax at 375 nm, ε375 of 43,000 M⁻¹ cm⁻¹) and NAD^+ are converted to 2-hydroxy-3-muconic acid and NADH (ε375 of 1,900 M⁻¹ cm⁻¹) were measured with an Agilent 8453 diode-array spectrometer. The reaction rate was calculated as the change in absorbance divided by the sum of the extinction coefficients of 2-HMS and NADH. Initial rates vs. substrate concentration was fitted with the Michaelis-Menten equation:

\[ \frac{v_0}{[E]_T} = \frac{k_{cat} \times [S]}{K_m + [S]} \]

**NMR Spectroscopy**—All NMR spectra were recorded on a Bruker (Billerica, MA) Avance III HD 500 MHz spectrometer equipped with a CryoProdigy Probe at 300 K running TopSpin 3.5p16. Spectra were recorded in D₂O or 90% H₂O/10% D₂O and referenced to residual solvent (¹H – 4.70 ppm). One-dimension ¹H spectra (pulse sequence: zg30) were recorded with 1 s relaxation delays, 64k data points, and multiplied with an exponential function for a line-broadening of 0.3 Hz before Fourier transformation. DQFCOSY (pulse sequence: cosygmfpqg) spectra were acquired with spectral widths of 13.0 ppm with 2k × 128 data points and a relaxation delay of 2.0 s. 1D gradient selected NOESY (pulse sequence: selnogp) were recorded with a mixing-time of 0.3 s, a 2 s relaxation delay, and multiplied with an exponential function for a line-broadening of 3 Hz before Fourier transformation. All NMR data were processed using MestReNova NMR v11.0.3 software.

**Mass Spectrometry**—The AMSDH reaction product, 2-aminomuconate, was isolated for mass spectrometric characterization by reverse phase HPLC with an InertSustain C18 column (5 µm particle size, 4.6 ID x 100 mm, GL Sciences Inc.) on a Dionex Ultimate 3000 HPLC equipped with a diode array detector (Sunnyvale, CA, USA). The crude reaction mixture was ultrafiltered (10 kDa cutoff) to remove protein, and separation was achieved using isocratic elution with 95% H₂O, 5% acetonitrile, and 0.5% formic acid. Mass spectra were collected on an maXis plus quadrupole-time of flight mass spectrometer equipped with an electrospray ionization source (Bruker Daltonics). The instrument was operated in the negative ionization mode in the range 50 ≤ m/z ≤ 1500, and calibrated using ESI-L Low Concentration Tuning Mix (Agilent Technologies). Samples were introduced via syringe pump at a constant flow rate of 3 µL/min. Relevant source parameters are summarized as follows: capillary voltage, 3500 V with a set end plate offset of –500 V; nebulizer gas pressure, 0.4 bar; dry gas flow rate, 4.0 L/min; source temperature, 200 °C. Mass spectra were averages of one minute of scans collected at a rate of 1 scan per second. Collision induced dissociation (CID) was achieved using a set collision energy of –20 eV. OtofControl software version 6.3 was used for data acquisition and Compass Data Analysis software version 4.3 (Bruker Daltonics) was used to process all mass spectra. mMass software version 5.5.0 was used for all exact mass calculations (30).

**Acknowledgments:** We thank Dr. Wendell Griffith for assisting the mass spectrometry analysis.

**Conflict of interest:** The authors declare that they have no conflicts of interest with the contents of this article.

**Author contributions:** AL and ID conceived of the study. ID and YY designed, performed, and analyzed biochemical experiments. DW performed and assisted analysis of NMR experiments. ID wrote the manuscript with input from AL and all authors.
References


FOOTNOTES

This work was supported in whole or part by the National Science Foundation grant CHE-1623856, the National Institutes of Health (NIH) grants GM107529, GM108988, MH107985, and the Lutcher Brown Distinguished Chair Endowment fund (to A.L.). The mass spectrometry facility was sponsored by National Institutes of Health Grant G12MD007591. The NMR spectrometer is a shared instrument sponsored by the National Science Foundation (NSF) under award no. 1625963.

†ID is also affiliated with the Department of Chemistry, Georgia State University, Atlanta, Georgia 30303.
### Table 1. Kinetic parameters of ALDH8A1 and mutants for 2-HMS

<table>
<thead>
<tr>
<th></th>
<th>$k_{\text{cat}}$ (s$^{-1}$)</th>
<th>$K_m$ (µM)</th>
<th>$k_{\text{cat}}/K_m$ (s$^{-1}$ M$^{-1}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALDH8A1</td>
<td>$0.42 \pm 0.03$</td>
<td>$0.59 \pm 0.10$</td>
<td>$7.1 \times 10^5$</td>
</tr>
<tr>
<td>R109A</td>
<td>$1.06 \pm 0.12$</td>
<td>$97 \pm 13$</td>
<td>$1.1 \times 10^4$</td>
</tr>
<tr>
<td>R451A</td>
<td>ND$^a$</td>
<td>ND</td>
<td>-</td>
</tr>
<tr>
<td>N169A/D/Q</td>
<td>$&lt; 0.02$</td>
<td>ND</td>
<td>-</td>
</tr>
</tbody>
</table>

$^a$ Not determined
Scheme 1. The kynurenine pathway. The enzymes identified in kynurenine pathway are: indoleamine 2,3-dioxygenase (IDO)/tryptophan 2,3-dioxygenase (TDO), N-formyl kynurenine formamidase (FKF), kynurenine 3-monooxygenase (KMO), kynurenic acid aminotransferase (KAT), kynureninase (KYNU), 3-hydroxyanthranilate-3,4-dioxygenase (HAO), 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD), and the proposed enzyme 2-aminomuconate semialdehyde dehydrogenase (AMSDH).
Scheme 2. Proposed spontaneous decay mechanism for 2-aminomuconate
Scheme 3. Coupled ACMSD:AMSDH assay performed in D$_2$O.
Figure 1. Sequence alignment of ALDH8A1 with HMSDH enzymes. Highly conserved residues are shown with red text and boxed in blue, strictly conserved residues are shown with a red background, and catalytic residues are shown with a green background. The enzymes chosen for alignment are as follows: ALDH8A1, GenBank: AA113863; AMSDH from Pseudomonas fluorescens, GenBank: BAC65304; HMSDH from Paraglaciecola arctica, Accession No: WP_007618756; ACSDH from Comamonas testosterone, Accession No: YP_001967696; AMSDH from Cupriavidus metallidurans, GenBank: KWW33428; AMSDH from Cupriavidus basilensis, GenBank: AJG18463; HMSDH from Pseudomonas sp. M1, GenBank: ETM66811; ESPript was used to create this figure.
Figure 2. Homology model of ALDH8A1 (green) and crystal structure of pfAMSDH, 4I26 (gray). Overlay of a single polypeptide (A), and a zoom-in of the active site with catalytically relevant residues (B).
Figure 3. Purification and representative activity assay of ALDH8A1. (A) SDS-PAGE of a purification by Ni-NTA affinity chromatography. Lane 1 is clarified cell extract, 2 is cell pellet, 3 is flow-through, and 4-7 are fractions 1-4, respectively. Fractions 2 and 3 were collected for use. (B) Time course of ACMSD acting on ACMS to produce 2-AMS which decays to PA. (C) Coupled-enzyme assay with ACMSD and ALDH8A1 converting ACMS to 2-AM in the presence of NAD⁺, and (D) Scheme showing the reactions in A and B as the top and bottom branches, respectively.
Figure 4. $^1$H-$^1$H NMR COSY spectrum of a coupled-enzyme reaction mixture containing 2-AM showing correlations of $H_b$ with $H_a$ and $H_c$. 
Figure 5. (A) UV-Vis spectrum of 2-AM and time course of its non-enzymatic decay (inset). (B) MS-MS spectrum of the 2-AM decay product.
Figure 6. $^1$H-NMR spectra monitoring the decay of 2-AM from a coupled-enzyme assay performed in H2O (A) and D2O (B). A zoom-in of the resonances corresponding to 2-AM and its decay product is inset in B. The initial and final spectra are shown as blue and black, respectively.
Figure 7. $^1$H NMR spectrum of 2-HMS (bottom) and 1D NOESY spectra show enol tautomer. NOESY spectra were acquired by irradiating at the resonance marked with an asterisk corresponding to the color-coded proton, H_d as blue, H_b as red, and H_αc as mustard. Out-of-phase, positive, resonances show through space interactions between protons, and in-phase, negative, resonances show the same proton in the enol tautomer as indicated by the isomerization shown.
Figure 8. Determination of Michaelis-Menten parameters of ALDH8A1 (A) and the R109A variant (B) for 2-HMS. Reactions were monitored by the decrease in absorbance at 375 nm.